Clinical Report: Efficacy and Safety of Darunavir and Lopinavir in Pediatric HIV

Overview

This systematic review evaluates the efficacy and safety of darunavir (DRV) and lopinavir (LPV) in treating HIV among pediatric and adolescent populations. The findings indicate that both medications are effective, with DRV showing better tolerability compared to LPV.

Background

HIV remains a significant health challenge for children and adolescents, with millions affected globally. The World Health Organization recommends early initiation of antiretroviral therapy (ART) for all children living with HIV, making it crucial to assess the efficacy and safety of available treatment options. Understanding the comparative effectiveness of protease inhibitors like DRV and LPV is essential for optimizing treatment strategies in this vulnerable population.

Data Highlights

No numerical data was provided in the article.

Key Findings

• Darunavir (DRV) and lopinavir (LPV) are both recommended for treating HIV in children and adolescents.
• DRV/r has been approved for use in children aged ≥ 3 years and is recommended as a second-line therapy if dolutegravir fails.
• LPV/r is recommended as a first-line alternative when dolutegravir is unsuitable.
• Formulation challenges exist with LPV/r, particularly regarding palatability and dosing.
• The systematic review synthesized data from 42 studies, supporting the effectiveness of both DRV and LPV/r.
• DRV demonstrated better tolerability compared to LPV/r, which faced more significant formulation issues.

Clinical Implications

Clinicians should consider the tolerability and formulation challenges associated with LPV/r when prescribing HIV treatments for children. The findings support the use of DRV as a preferred option in cases where LPV/r may pose difficulties due to its formulation and palatability issues.

Conclusion

The systematic review highlights the efficacy and safety of DRV and LPV in pediatric HIV treatment, with DRV emerging as a more favorable option due to its better tolerability. These insights are critical for guiding future treatment recommendations.

References

1. Open Forum Infectious Diseases, 2023 -- Drug Resistance to HIV-1 in Pediatric Populations: Insights from a Systematic Review and Meta-Analysis on Treatment Implications
2. Infection, 2007 -- Efficacy and Challenges of Indinavir/Low-dose Ritonavir-Based HAART in Pediatric HIV-1 Patients: Strong Antiretroviral Effects Coupled with Adverse Reactions and High Treatment Discontinuation Rates
3. Drug Safety, 2022 -- Management Strategies for Idiosyncratic Drug-Induced Liver Injury and Acetaminophen-Related Hepatotoxicity in Children: A Comprehensive Review
4. The Journal of Infectious Diseases, 2023 -- In-depth Analysis of the HIV Reservoir Confirms Effectiveness and Safety of Dolutegravir/Lamivudine in a Phase 4 Randomized Controlled Switch Trial (RUMBA)
5. Pediatric Guidelines - Full Guidelines, 2025 -- Pediatric HIV Treatment Guidelines
6. Effectiveness and safety of darunavir and lopinavir for treating children and adolescents living with HIV: a systematic review, 2023
7. Update to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, 2025
8. Pediatric Guidelines - Full Guidelines
9. Effectiveness and safety of darunavir and lopinavir for treating children and adolescents living with HIV: a systematic review - PMC
10. Update to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection | HIV.gov